Sign in to view content

Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials

Glenn J. Jaffe, MD

Video
Published 2023

Related

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Annual Meeting Talks
2021
Is It Necessary to Peel Internal Limiting Membrane in Diabetic Vitrectomy
Stanley Chang, MD
Updates from the Field
2022
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Macular Pucker - Epiretinal Membrane

See more